T cells are a broad class of adaptive immune cells, while CD8⁺ T cells are a specific, specialized subset of T cells, defined by the presence of the CD8 surface receptor. T cells, matured in the thymus, consist of helper, cytotoxic and regulatory functions. This study aimed to evaluate the clinical importance of Tumor Infiltrating Lymphocytes (TILs) as well as CD8⁺ T cells in patients with early-stage breast cancer (eBC) treated with dose-dense sequential chemotherapy. The researchers aim to assess tumor samples for TILs and CD8⁺ T cells from eBC patients using immunohistochemistry (IHC). In particular, we will measure the following parameters: CD8+ T cells found in the tissue around the tumor \[stromal\], CD8+ cells found inside the tumor \[intratumoral\], the total number of CD8⁺ cells as well as stromal TILs \[cells in the surrounding tissue\]. The main point of this study was to better understand the way these immune cells are associated with patients' outcome in a large group of patients with eBC who were treated initially with surgery and then received a dose-intense adjuvant chemotherapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To investigate the long-term prognostic significance of TILs & CD8+ in term of OS
Timeframe: Time from study entry to death from any cause, assessed up to 120 months
To investigate the long-term prognostic significance of TILs & CD8+ in term of DFS
Timeframe: Time from study entry to first recurrence (local, regional, distant) or death from any cause, whichever comes first, assessed up to 120 months
To investigate the long-term prognostic significance of TILs & CD8+ in term of iBCFS
Timeframe: Time from study entry to invasive breast cancer recurrence or death, whichever comes first, assessed up to 120 months